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TH1 DERIVED cytokines IFN-g and IL–2, Th 2 cytokine IL–
4, and ICAM–1 have been implicated in liver allograft
rejection. In order to determine whether monitoring
of  cytokine  profiles during the  first  days  post-liver
transplant  can predict early rejection we measured
IFN-gg, IL–2, sIL–2 receptor, IL–4 and ICAM–1 in 22
patients, in plasma samples obtained within 4 h after
liver perfusion (baseline) and between postoperative
days (POD) 3–6. ICAM–1 and sIL–2R levels at POD 3–6
were significantly higher than at baseline but did not
differ  in  presence  or  absence  of  rejection.  Mean
percentage  increase  of  ICAM–1  levels  was  signifi-
cantly lower in patients with Muromonab-C3 Ortho-
clone OKT3 (J.C.  Health Care )  (OKT3 )  whereas per-
centage  increase  of  sIL–2R  levels  was  higher  in
OKT3-treated  patients.  IFN-g levels  at  POD  3–6
increased  from  baseline  while  IL–4  levels  were
unchanged. Levels of IFN-g , IL–4 and their ratios did
not correlate with  rejection or immunosuppressive
therapy.  Thus,  Th 1/Th 2 cytokine monitoring during
the first week post-transplant does not predict early
rejection  and  immunosuppressive  therapy  is  the
predominant factor affecting ICAM and sIL–2R levels
after liver transplantation.
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Introduction
Cytokines  play  a  pivotal  role  in  modulation  of  the
immune response following solid organ transplanta-
tion. A distinct array  of cytokines produced by two
subsets  of  CD4+  helper T  cells, Th1 and Th2,  dic-
tates  induction  and  regulation  of  cellular  and
humoral immunity. The Th1 subset secretes IL–2, IL–
3,  IFN-g and TNF,  which  subsequently  also  induce
expression of adhesion molecules, whereas Th2 cells
produce IL–4, IL–5, IL–6 and IL–10.1,2 The Th1/Th2
paradigm  is  based  on  the  hypothesis  that  a  Th1
immune  response  is  detected  in  hosts  undergoing
rejection  whereas  an immune  pattern  that  deviates
towards  a Th2 response  is  associated  with  allograft
tolerance.2 Increased  plasma TNF  levels  have  been
shown to precede rejection in both liver and kidney
transplant  patients  and  IL–2  and  IFN-(have  been
consistently  detected  in  hosts  undergoing  unmodi-
fied  acute  rejection.3 –6 IL–4  has  been  noted  to  be
preferentially  associated  with  allograft  engraft-
ment.7–9 Yet, elevated IL–4 levels are also evident in
rejecting patients, most notably in those with spon-
taneously  resolving  rejection.10,11 This  increase  in
IL–4  levels  occurs  at  a  later  time  point  than  the
increase in IL–2 levels, likely indicating amelioration
of  the  rejection  episode.  Further  studies  have  sug-
gested that  rather than absolute levels of individual
cytokines it is the ratio of Th1/Th2 cytokines which
serves  in  determining  allograft  rejection  or
tolerance.9
In  order  to  further  elucidate  the  efficacy  of
cytokine  monitoring  in  predicting  rejection  we
serially monitored Th1 cytokines IL–2 and IFN-g , the
Th2 cytokine IL–4 and ICAM–1 levels in liver trans-
plant patients during the first week post-transplant.
Materials and Methods
Patients
Twenty-two patients undergoing an orthotopic liver
transplant  were  studied.  Plasma  samples  were
obtained  from  each  patient  within  4h  after  liver
perfusion  and  on  postoperative  days  (POD)  3  and
6.
Data  analysed included:  primary  immunosuppres-
sion,  early  graft  function  (poor  early  graft  function
was  defined  as  prothrombin  time  (PT)  >18 s  on
POD 2 and peak aspartate aminotransferase (AST) or
alanine  aminotransferase  (ALT)  >2500  units  during
the first 3 postoperative days), evidence of infection
(based on cultures of blood, sputum, urine, wounds
and  drains,  cytomegalovirus  (CMV)  serology  and
CMV  cultures)  and  histologically  proven  rejection
during the first 2 weeks post-transplant.
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Levels of IL–2, soluble IL–2 receptor (sIL–2R), IFNg ,
IL–4  and  ICAM–1  were  determined  (in  duplicate
aliquots)  for  each  plasma  sample,  by  commercial
ELISA  kits  (R+D  Systems,  Minneapolis,  MN).  The
absolute  cytokine  level  was  calculated  based  on  a
standard curve provided by the manufacturer.
Data analysis
For each cytokine mean patients’ absolute levels at 4 h
post-perfusion (baseline levels) were compared with
mean absolute levels at 3 and 6 POD. Data were also
analysed by calculating the mean change in cytokine
levels, e.g. each patient’s baseline levels at 4h post-
perfusion were expressed as 100%, and the patient’s
cytokine  levels  at  3  and  6  POD  expressed  as  per-
centage  of  baseline. The  percentage  increase  from
baseline  to  levels  at  POD  3  and  6  was  compared
among  patients  with  and  without  rejection  and
among those receiving cyclosporine A (CsA) or OKT3
as  primary  immunosuppression.  Results  were  com-
pared  by  the  Mann–Whitney  test  and  by  one-way
analysis of variance (ANOVA).
Results
Of the patients studied there were 11 males and 11
females, with an age range of 49.4 ± 8.9 (mean ± SD).
Indication  for  transplantation  was  hepatitis  C  virus
(HCV) cirrhosis in 13 patients, hepatitis B virus (HBV)
in two, cryptogenic cirrhosis in one, primary biliary
cirrhosis  in  two,  autoimmune  liver  disease  in  two,
fulminant liver failure in one, and primary sclerosing
cholangitis  in  one.  This  diversity  precluded  data
analysis  according  to  primary  liver  disease.  The
primary  immunosuppressive drug  was cyclosporine
in 15 patients and OKT3 in seven patients.
In nine patients no rejection episodes were docu-
mented within the first 12 days post-transplant. In 13
patients rejection was diagnosed during the first 12
days  post-transplant  (in  six  patients  rejection  was
diagnosed during days 6–8 post-transplant.
Cytokines
IL–2 levels were non-detectable in all plasma samples
studied.  sIL–2R  levels  increased  from  74.8  ±
11.8 pmol/ml  (mean  ±  standard  error)  at  4 h  post-
perfusion  to  171.4  ± 23 pmol/ml at  POD  3–6, P <
0.001. The mean percentage increase from baseline
levels was significantly higher in patients with OKT3
induction  compared  with  cyclosporine  treated
patients: 531.5% ± 140.8 vs. 237.7% ± 32.3, P < 0.001.
Mean percentage increase from baseline did not differ
in  the  presence  or  absence  of  rejection  (305.3%  ±
70.7 vs. 366.6% ± 104.4).
Mean levels of IFN-g at POD 3–6 were significantly
increased compared with post-perfusion levels; from
111 ± 28 pg/ml post-perfusion to 163 ± 39 pg/ml at
POD 3–6, P < 0.05. Mean percentage increase from
baseline  did  not  correlate  with  rejection  episodes
(rejection vs. no-rejection: 181.1% ± 50.1 vs. 206.4% ±
68.7) or immunosuppressive therapy (CsA 231.2% ±
47.8 vs. OKT3 227.6% ± 85.4).
ICAM–1  levels  at  3–6  days  post-transplant  were
significantly higher than baseline post-perfusion lev-
els; 431 ± 38.6 pg/ml vs. 223 ± 44.0 pg/ml, P < 0.001.
Percentage increase in ICAM–1 levels (baseline levels
expressed as 100%) did not differ in the presence or
absence  of  rejection  (272.9%  ±  45.0  vs.  295.1%  ±
85.8,  mean  ±  standard  error).  Mean  percentage
increase  from  baseline  was  significantly  lower  in
patients  with  OKT3 induction  compared  with  CsA-
treated patients; 216.4% ± 33.4 vs. 312.7% ± 63.6, P <
0.01.
No correlation was observed between percentage
increase in IFN-g levels and the increase in ICAM–1
levels  (for  all  patients  R2 =  0.09,  in  patients  with
rejection R2 = 0.02).
IL–4 levels were unchanged during the time period
studied. Mean baseline levels 678.5 ± 46.8 pgm/ml vs.
650.5 ± 50.1 pg/ml at POD 3–6. Levels were similar in
the presence or absence of rejection and in OKT3 and
CsA-treated patients.
The ratios of IL–4/IFN-g remained unchanged over
time; 14.3 ± 3.7 post-perfusion vs. 13.1 ± 5.6 at POD
3–6. Although the ratio of IL–4/IFN-g at both baseline
and  POD  3–6  was  lower  in  patients  experiencing
early rejection compared with patients without rejec-
tion, differences were not statistically significant.
Discussion
In  post-liver transplant patients serial  monitoring of
plasma Th1 cytokines IL–2 and IFN-g , Th2 cytokine IL–
4 and the adhesion molecule ICAM–1 during the first
week  post-transplant  did  not  enable  prediction  of
early rejection.
In our patients IL–2 levels were non-detectable in
all plasma samples studied. IL–2 was non-detectable
even at baseline measurements within  the first few
hours  post-liver  perfusion  denoting  that  the  initial
dose of immune suppressive therapy (CsA or OKT3 ) is
sufficient  to  abolish  IL–2  release  from  activated
lymphocytes. IL–2 levels were similarly nonmeasur-
able in the 13 patients in whom early rejection was
diagnosed. An  increase  in  IL–2  levels  is  frequently
observed  in  transplant  recipients  experiencing  epi-
sodes of rejection10,12,13 but have not been found, in
all studies, to be sufficiently reliable to diagnose or
exclude  rejection.5 Indeed,  Baan  et  al.11 noted
intragraft IL–2 mRNA expression in only 36% of post-
liver  transplant  patients  with  rejection.  In  renal
transplant recipients studied during the first 14 days
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predictive of impending graft rejection and increased
a  mean  2.8  days  prior  to  clinical  diagnosis  of
rejection.10 Although rejection was diagnosed in six
of our patients as early as days 6–8 post-transplant, no
elevation in IL–2 levels was evident.
Soluble IL–2 receptor levels were increased at POD
3–6 in all patients, both in the absence and presence
of  rejection. The  highest  levels  were  measured  in
patients  whose  primary  immunosuppression  was
OKT3, thereby likely denoting the marked degree of
cytolysis  which  occurs  following  OKT3
administration.
Monitoring of IFN-g levels was also of no predictive
value regarding early rejection. Levels increased to a
similar  degree  in  all  patients  during  the  first  week
post-transplant  corroborating  findings  of  a  previous
study  in  renal  transplant  patients  in  whom rises  in
IFN-g levels during the first 2 weeks post-transplant
was not associated with rejection.14 IFN-g is one of
the major inducers of ICAM–1 but changes in IFN-g
levels  did  not  correlate  with  changes  in  ICAM–1
levels  (analysed  both  for  all  patients  and  for  the
rejection  group). Although  significant  elevations  in
ICAM–1 levels have been reported in renal transplant
patients  2–3  days  prior  to  diagnosis  of  clinical
rejection,14 in our patients rejection was not accom-
panied by changes in ICAM–1 levels. Multiple factors
appear to affect plasma ICAM–1 levels; preoperative
ischaemic injury, reperfusion injury, graft dysfunction
and infections.15–17 Of the infectious pathogens, CMV
is remarkable in its ability to upregulate expression of
adhesion  molecules  on  infected  cells.18 Among  our
patients,  seven  had  infectious  episodes  diagnosed
during  the  study  period  and  although  in  none was
CMV  infection  diagnosed three were CMV negative
prior to transplantation from a CMV positive donor.
Thus, the numerous variables affecting plasma ICAM–
1  levels  preclude  the  use  of  this  parameter  in
predicting rejection. Our findings point to immuno-
suppressive therapy as a major determinant of ICAM–
1 levels as these were significantly lower in patients
receiving primary immunosuppression with OKT3.
Levels of the Th2 cytokine IL–4 remained relatively
stable throughout the first week post-transplant in all
patients  studied,  and  did  not  correlate  with  the
absence or presence of rejection. A previous study, in
renal transplant recipients, reported that the highest
IL–4 levels are detected late in the course of clinical
rejection  suggesting  that  the  rise  in  IL–4  levels
coincides with resolution of the rejection episode.10
This  observation  is  in  accord  with  findings in  liver
transplant  patients  in  whom  intragraft  IL–4  mRNA
expression  was  detected  in  70%  of  biopsies  with
histological  evidence  of  rejection  obtained  from
patients  without  clinical  signs  of  rejection.  In  con-
trast, IL–4 mRNA expression was present in only 19%
of  biopsies  without  rejection  and  18%  of  biopsies
with  histological  evidence  of  rejection  and  con-
current graft dysfunction.11 Thus, in our patients, as
plasma  IL–4  levels  were  determined  not  later  than
POD 6, a later rise in  IL–4  may  have  been missed.
Interestingly, Gorczynski et al.19 observed equivalent
transcription of IL–4 in peripheral blood lymphocytes
and  liver  biopsies  of  all  liver  transplant  patients,
regardless of rejection status. Furthermore, levels of
another Th2 cytokine, IL–10, which are expected to
rise in patients with uncomplicated transplants do not
differ in rejecting and non-rejecting patients nor does
intragraft expression of IL–10 mRNA differ between
uncomplicated transplants, acute and chronic rejec-
tion or normal liver controls.20
The late rise in IL–4, compatible with a role for Th2
cells  in  suppressing  the  Th1 dependent  immune
response, has suggested that the Th1/Th2 balance may
be  more  predictive  of  the  immune  response  than
individual cytokine levels. Yet, in post-liver transplant
children the IFN-g /IL–4 ratio could not discriminate
between  infectious  episodes,  other  than  CMV  and
rejection.21 In  our  study,  although  in  patients  with
rejection the IFN-g /IL–4 ratio was higher than in non-
rejecting patients, differences did not reach statistical
significance.
In summary, our observations do not support a role
for cytokine monitoring, during the first week post-
OLT, in predicting early rejection. Plasma levels of sIL–
2R,  ICAM–1,  IFN-g ,  IL–4  and  their  ratios  do  not
correlate with rejection. Notably, immunosuppressive
therapy  is  the  predominant  factor  affecting  plasma
sIL–2R and ICAM–1 levels after liver transplantation.
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